Search PubMed⌕ Search

Biomedical subjects

K Kamoi

Publications and source records attributed to K Kamoi.

At least 109 records · Page 6Linked to original sources

Hyperthyroidism caused by a pituitary thyrotrophin-secreting tumour with excessive secretion of thyrotrophin-releasing hormone and subsequently followed by Graves' disease in a middle-aged woman.

A 46-year-old woman had signs of thyrotoxicosis and galactorrhoea. Serum immunoreactive TSH and its alpha-subunit increased in the presence of high serum triiodothyronine (T3), thyroxine (T4), and free T4 concentrations, whereas beta-subunit TSH was undetectable. Exogenous TRH failed to increase serum TSH. Serum TSH was markedly suppressed by glucocorticoid, but was increased by antithyroid drug. L-Dopa or bromocriptine partially suppressed, but nomifensine had no influence on serum TSH. Serum prolactin (Prl) was above normal and markedly increased by TRH, but depressed by bromocriptine and not suppressed by nomifensine. Plasma TRH was normal in the hyperthyroid state, but was increased by glucocorticoid and antithyroid drug. Excess thyroid hormone depressed plasma TRH concentrations. Basal serum GH levels were constantly low. Transsphenoidal removal of the tumour normalized serum hormones (T3, T4 free T4, TSH, alpha-subunit and Prl), and eradicated the clinical signs of hyperthyroidism and galactorrhoea. Histological study of the tumour tissue demonstrated both thyrotrophes and somatotrophes. A reciprocal relationship between serum TSH and T4 concentrations shifted to a higher level before but was normalized after removal of the tumour. Ten months later, the clinical signs of thyrotoxicosis and the increase in serum thyroid hormone recurred without a concomitant increase in serum TSH and its alpha-subunit. Thyroidal auto-antibodies were slightly positive, but thyrotrophin-binding inhibitor immunoglobulin (TBII) was negative. Administration of antithyroid drug produced a euthyroid state, but 3 years later, discontinuation of the treatment resulted in recurrent hyperthyroidism without suppressed plasma TRH and with no evidence of regrowth of the pituitary tumour. It is suggested that the patient initially had hyperthyroidism owing to excessive TSH secretion from the tumour caused by abnormal TRH secretion, and subsequently had hyperthyroidism owing to Graves' disease.

Adenoma↗

Reduction of hypothalamic norepinephrine does not alter the osmoregulation of vasopressin in rats.

The supraoptic nuclei of the hypothalamus are known to be heavily innervated by noradrenergic neurons. However, the role of these neurons in regulating secretion of the antidiuretic hormone, arginine vasopressin, remains unsettled. In an effort to clarify this question, we studied the effect of multiple small doses of D,L alpha-methyl-p-tyrosine (alpha-MpT) on hypothalamic norepinephrine and the osmoregulation of vasopressin in rats. We found that, at the doses employed (80 mg/kg every 6 h for 24 h), alpha-Mpt reduced mean (+/- SD) hypothalamic norepinephrine by about 50% but did not affect plasma osmolality, sodium, glucose, urea, or vasopressin either under basal conditions or during osmotic stimulation by ip injection of hypertonic saline. During the latter, plasma vasopressin correlated directly with plasma osmolality and the regression lines that described the relationships in the control and drug-treated rats were identical. Hematocrit and mean arterial pressure were also unaffected by alpha-MpT. These findings do not support the concept based on previous studies that central noradrenergic pathways mediate the vasopressin response to osmotic stimuli.

Animals↗